Chemometec A/S
Preliminary revenue figures for the 2024/25 financial year
Preliminary revenue figures for the 2024/25 financial year
ANNOUNCEMENT NO. 290
1 July 2025
Preliminary revenue figures for the 2024/25 financial year
Based on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 496 million for the financial year 2024/25, against the previously announced DKK 470-490 million.
ChemoMetec’s annual report for 2024/25 is scheduled to be released on 11 September 2025.
Additional information
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Trifork Group AG1.7.2025 22:08:34 CEST | Press release
38/2025・Trifork Group: Weekly report on share buyback
Constellation Brands, Inc.1.7.2025 22:05:49 CEST | Press release
Constellation Brands Reports First Quarter Fiscal 2026 Financial Results
Vastned NV1.7.2025 18:00:00 CEST | Press release
Disclose of Transparancy Declaration (article 14, first paragraph, of the Law of 2 May 2007)
Ageas1.7.2025 17:40:00 CEST | Press release
Ageas completes the acquisition of Saga's Underwriting Business
Pharma Equity Group A/S1.7.2025 17:31:07 CEST | Press release
The Board of Directors' resolution on the issuance of convertible loans
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom